Sotagliflozin Safety and Tolerability Among Renal Transplant Recipients

PHASE2CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

October 17, 2022

Primary Completion Date

May 10, 2024

Study Completion Date

November 16, 2024

Conditions
Kidney Transplant
Interventions
DIAGNOSTIC_TEST

eGFR reporting

"To test the proportion of patients successfully completing the protocol according to different eGFR reporting strategies, randomization in a 1:1 fashion at the patient level (n=50) will occur as follows:~1. only study-related eGFR values \>25% below baseline will be reported to patients and providers~2. all study-related eGFR will be provided to patients and providers"

Trial Locations (1)

02115

Brigham and Women's, Boston

All Listed Sponsors
lead

Martina McGrath, MD

OTHER